Add to GENMED scammers list of fraudulent promoters
===============================================
It Could Make You 5 Times Richer By Summer...
Your First Rapid 510% On Genmed (GENM) Could Be
In Your Hands In 100 Days Or Less... Then, You Could
Make As Much As 989% Before Snow Flies!
Dear Micro-Cap Investor:
Today's media machine doesn't let investment sweet spots like this last for long. Outstanding opportunities, like the one you're about to see, are ripe today... and devoured by hungry investors tomorrow.
And this one is sweet. It is the one you've been waiting for.
You could pocket your first 510% success in less than 100 days... then watch as that could double by Christmas... a 10 bagger The Death Of Communism Has Created
A Vast, Unprecedented Opportunity For
Big-Picture Investors Who Know The
Power Of Free Markets
All you have to do is get out ahead of the newest MEGA TREND that's developing in Europe's drug sector. It is a big deal... one that gets bigger every day.
This is a fast-expanding market that was cracked wide open when much of Europe cast off the shackles of communism and embraced the American form of Capitalism.
Andy Carpenter
Carpenter Global Stock Advisory
ACTION ALERT
Genmed
SYMBOL
GENM
And, one company I've discovered looks poised to claim a highly profitable corner of this quarter-trillion-dollar market. The company is Genmed (GENM). It sells products in the booming generic-drugs market.
My Top Picks Tend To Explode...
Rapidly Jumping 289%... 576%... 669%
Hello, my name is Andrew Carpenter, editor of the Carpenter Global Stock Advisory. Some people call me the "maverick genius of the micro-cap market."
I am known for finding soon-to-be-hot companies just before they pop...this talent for finding hidden gems has led major global newspapers, such as The Wall Street Journal, USA Today and The Shanghai Security News to write huge profiles about me.
In fact, The Wall Street Journal said that I have an uncanny knack for discovering companies... "that fly below the radar screens of most Wall Street analysts," and that I "Dig up information on companies Wall Street can't be bothered with." USA Today said that I... "Predicted one stock winner after another."
So people pay attention when I announce a new discovery. Many of them will read a new Special Report I have written about Genmed (GENM), which your can read for FREE today just below here.
Genmed (GENM)
It Could Be Your Best Global Opportunity Of The Year
You can access it for FREE as part of an introduction to my newsletter... but you're under no - obligation... I won't even ask for you email address. FREE is free to me.
You see, I've been looking for a company in the super-hot European drug sector... in particular, not some old, tired dinosaur... rather, I sought a young company... one with start-up power... and the potential to give you explosive - gains. GENMED fills that bill.
Genmed's Supplier Has Increased Production 300%
To Keep Up With GENM's Demand
The Special Report covers all Genmed's tremendous upside... its rip-roaring potential to dominate the generic drug sector.
In my Genmed Special Report you see...
• How the big players of old are suddenly at a disadvantage to young Genmed (GENM)...
• Why one of Genmed's suppliers had to increase production by 300% just to keep up with orders...
• Why Holland and the Czech Republic could hold the key to your fortunes...
• Why a new agreement in England opens a 1,200-pharmacy, 500-hospital market...
• How this final wave of European privatization could multiply your money by nearly 10X by Christmas.
There Is A Massive Demand For Less - Expensive Drugs... Genmed
Looks Set To Shoot At Least 510% By July 4, Because It's Selling FDA Approved Generic Drugs In A Huge, Newly Deregulated Market
So, let's get you to the Special Report now... take moment of your time to discover what could be one of the most important companies in the newly booming European drug sector... a company you could own today for pennies!
And, thanks for your time today.
Andrew Carpenter,
Editor, The Carpenter Global Stock Advisory
P.S. Please don't lose sight of the fact that as generic drug sales are set to boom in Europe after years of being held in check, Genmed is lined up and ready to supply Europe with top selling generic drugs.
And, you can be there to capture all the potential - what could be as much as 510% by this summer... and the possibility to see it double after that.
You'll find it all here for FREE.
IMPORTANT NOTICE AND DISCLAIMER: Andrew Carpenter's (Endorser) track record was compiled from calculations derived from documentation of his Carpenter Global Stock Advisory (CGSA) newsletter. Said newsletter and documentation were made available to CGSA subscribers. No representation is made that actual purchases and sales were made at the prices stated. Facts stated in this article were supplied to endorser from third-party sources. Endorser makes no representations as to such facts' reliability, accuracy or completeness. Endorser is not responsible for errors or omissions. Endorser does not claim any special expertise or knowledge regarding the European generic or pharmaceutical drug sector or of its OTC drug sector. Endorser is neither acting as an investment advisor nor providing individual investment - advice. Andrew Carpenter and The Carpenter Global Stock Advisory OWN NO SHARES, OPTIONS, WARRANTS in Genmed Holding Corp. (GENM), Also, GENM neither approved nor paid for this specific advertisement. Readers should perform their own due diligence. The information presented is provided for information purposes only and the endorsement is not to be used or considered as an offer or the solicitation of an offer to sell or to buy or subscribe for securities. Endorser has not taken any steps to ensure that the securities referred to in this report are suitable for any particular investor. Any securities referenced by Endorser may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about such investments. Nothing in the endorsement constitutes investment, legal, accounting or tax advice or a representation that any investment or strategy is suitable or appropriate to your individual circumstances or otherwise constitutes a personal recommendation to you. Information, opinions and estimates referenced in the endorsement reflect a judgment at its original date of publication and are subject to change without notice. The price and value of the securities mentioned in the endorsement can fall as well as rise, and may have a high level of volatility. High volatility securities may experience sudden and large falls in their value, leading to losses. High volatility investments may also be difficult to sell. Similarly, it may prove difficult for you to obtain reliable information about the value or risks to which such an investment is - exposed. The endorsement may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of Endorser, Endorser has not reviewed any recommended or linked site and takes no responsibility for the content contained therein. Such address or hyperlink is provided solely for your convenience and information and the content of the linked site does not in any way form part of the endorsement. Accessing such websites or following any link shall be at your own risk. Further, you are advised to read and carefully consider the additional explanations of risk factors in Genmed Holding Corp's SEC filings that can be found online in the SEC's EDGAR database at www.SEC.gov. Neither Andrew Carpenter nor his publication is offering securities for sale. Carpenter has been contracted to receive five thousand dollars by a third party, Wellington Manner LLC, for coverage of Genmed Holding Corp. In addition, the Carpenter Global Stock Advisory expects to receive new subscriber revenue as a result of this advertising effort. Finally, Penny Stocks are EXTREMELY RISKY. You should consult with your registered investment adviser before investing to determine suitability and risk tolerance. Andrew Carpenter and The Carpenter Global Stock Advisory assume no risk for investor losses or profits. The information contained herein contains forward - looking information within the meaning of section 27a of the Securities Act of 1993, as amended, and section 21e of the Securities - Exchange Act of 1934, as amended, including statements regarding expected growth of the featured company. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act, statements contained herein that look - forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the Genmed Holding's actual results of operations. Factors that could cause actual results to differ include size and growth of the market, the Company's ability to fund its capital requirements in the near term and in the long term; pricing pressures, technology issues etc. There is no guarantee that past results are indicative of future performance
